Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $133.19

Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) have earned an average rating of “Moderate Buy” from the nineteen research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $131.1250.

RYTM has been the topic of several recent analyst reports. Bank of America reduced their target price on Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating on the stock in a report on Tuesday. Telsey Advisory Group set a $143.00 price target on Rhythm Pharmaceuticals in a report on Thursday, March 12th. Stifel Nicolaus set a $131.00 price target on Rhythm Pharmaceuticals in a research report on Thursday, February 26th. TD Cowen reiterated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 22nd.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Several major Wall Street firms lowered price targets but retained buy/overweight ratings, leaving substantial upside in consensus targets (new PTs reported in roughly the $100–$152 range). That continued analyst support may limit longer-term downdraft if management provides mitigating data or subgroup benefit. Analyst Reactions
• Positive Sentiment: A recent valuation piece argues that the stock’s pullback has improved entry valuation relative to its long-term return profile, suggesting some investors may view the decline as a buying opportunity if they believe in Rhythm’s broader franchise and pipeline. A Look At Rhythm Pharmaceuticals Valuation
• Neutral Sentiment: Rhythm released a transcript/slideshow discussing topline results and management insights from the Phase 3 EMANATE program; this provides more context but investors will need the full dataset and company guidance to reassess commercial and regulatory prospects. EMANATE Transcript & Slides
• Negative Sentiment: Multiple reports confirm Imcivree failed its late‑stage EMANATE weight‑loss trial for the targeted rare obesities, which directly increases near‑term clinical, regulatory and revenue uncertainty and was the primary driver of the share decline. Investors should watch for detailed efficacy/safety tables, any subgroup signals noted by management, and the company’s planned next steps. BioSpace: Imcivree Fails MSN: Trial Failure Coverage

Insider Activity at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total transaction of $502,789.84. Following the completion of the sale, the chief accounting officer owned 160 shares of the company’s stock, valued at $14,329.60. This represents a 97.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Hunter C. Smith sold 4,385 shares of the stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total transaction of $444,025.10. Following the sale, the chief financial officer directly owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 27,267 shares of company stock worth $2,719,955 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. lifted its position in shares of Rhythm Pharmaceuticals by 32.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 11,771 shares of the company’s stock worth $1,260,000 after purchasing an additional 2,903 shares in the last quarter. Invesco Ltd. grew its position in Rhythm Pharmaceuticals by 102.8% in the fourth quarter. Invesco Ltd. now owns 291,150 shares of the company’s stock valued at $31,165,000 after purchasing an additional 147,595 shares in the last quarter. Empowered Funds LLC grew its position in Rhythm Pharmaceuticals by 94.1% in the fourth quarter. Empowered Funds LLC now owns 4,164 shares of the company’s stock valued at $446,000 after purchasing an additional 2,019 shares in the last quarter. XTX Topco Ltd bought a new position in Rhythm Pharmaceuticals in the fourth quarter valued at $1,117,000. Finally, Wellington Management Group LLP grew its position in Rhythm Pharmaceuticals by 922.0% in the fourth quarter. Wellington Management Group LLP now owns 250,156 shares of the company’s stock valued at $26,777,000 after purchasing an additional 225,679 shares in the last quarter.

Rhythm Pharmaceuticals Stock Performance

RYTM opened at $85.86 on Friday. The firm’s fifty day moving average is $99.45 and its two-hundred day moving average is $102.69. The firm has a market cap of $5.86 billion, a PE ratio of -27.61 and a beta of 2.06. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The company had revenue of $57.25 million during the quarter, compared to analyst estimates of $56.16 million. During the same quarter in the previous year, the business earned ($0.72) EPS. The firm’s revenue was up 36.9% on a year-over-year basis. Equities analysts forecast that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.